Section Arrow
SRZN.NASDAQ
- Surrozen
Quotes are at least 15-min delayed:2026/04/23 14:02 EDT
Regular Hours
Last
 31.96
-1.07 (-3.24%)
Day High 
33.03 
Prev. Close
33.03 
1-M High
33.96 
Volume 
93.32K 
Bid
32.03
Ask
32.2
Day Low
31.735 
Open
33.03 
1-M Low
23.63 
Market Cap 
379.41M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 30.76 
20-SMA 29.13 
50-SMA 27.37 
52-W High 33.96 
52-W Low 5.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-32.37/-3.70
Enterprise Value
384.75M
Balance Sheet
Book Value Per Share
-16.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.48M
Operating Revenue Per Share
1.09
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ALTAltimmune2.86-0.61-17.58%-- 
REPLReplimune Group2.75+0.48+21.15%-- 
VRAXVirax Biolabs Group Limited0.15255+0.01755+13.00%-- 
IOVAIovance Biotherapeutics3.435-0.095-2.69%-- 
RXRXRecursion Pharmaceuticals3.495-0.235-6.30%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.